Messaggi chiave
- Si presentano i risultati di CamRelief, uno studio multicentrico di fase III, randomizzato, in doppio cieco, che si è proposto di valutare l’efficacia e la sicurezza dell’anticorpo anti-PD-1 camrelizumab in associazione a chemioterapia (CT) rispetto a placebo + CT nel trattamento neoadiuvante di pazienti con carcinoma mammario triplo negativo (TNBC) in stadio precoce o localmente avanzato.
- È stato arruolato un totale di 441 pazienti. Dopo un follow-up mediano di 14,4 mesi, il tasso di risposta patologica completa (pCR), l’endpoint primario dello studio, è risultato pari al 56,8 vs 44,7% nel gruppo camrelizumab + CT rispetto al gruppo trattato con sola CT (differenza tra i tassi, 12,2%; IC 95%, 3,3%-21,2%; p unilaterale = 0,004). Nella fase neoadiuvante, eventi avversi (EA) di grado ≥3 sono stati osservati nell’89,2 vs 83,1% delle pazienti dei due gruppi, con un’incidenza di EA seri del 34,7 vs 22,8% e due EA fatali associati al trattamento sperimentale.
- I risultati dello studio suggeriscono che, in pazienti con TNBC precoce/localmente avanzato, una strategia terapeutica neoadiuvante con camrelizumab in aggiunta alla terapia citotossica standard consente di ottenere un miglioramento statisticamente significativo del tasso di pCR rispetto alla sola chemioterapia, con un profilo di sicurezza gestibile e un trend verso il miglioramento degli esiti di sopravvivenza.
Abstract
Importance
- Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum.
- Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy.
- Camrelizumab, an anti-PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.
Objective
- To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with early or locally advanced triple-negative breast cancer.
Design, setting, and participants
- This randomized, double-blind, phase 3 trial enrolled patients from 40 hospitals in China between November 25, 2020, and May 12, 2023 (data cutoff: September 30, 2023).
- A total of 441 eligible patients were enrolled.
Interventions
- Patients were randomized in a 1:1 ratio to receive either camrelizumab 200 mg (n = 222) or placebo (n = 219) combined with chemotherapy every 2 weeks.
- The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by epirubicin (90 mg/m2) and cyclophosphamide (500 mg/m2) every 2 weeks for 8 weeks.
Main outcomes and measures
- The primary end point was pathological complete response (defined as no invasive tumor in breast and lymph nodes [ypT0/Tis ypN0]).
Results
- Among 441 females randomized (median age, 48 years), the median (range) follow-up duration from randomization was 14.4 (0.0-31.8) months.
- Pathological complete response was achieved in 126 patients (56.8% [95% CI, 50.0%-63.4%]) in the camrelizumab-chemotherapy group and 98 patients (44.7% [95% CI, 38.0%-51.6%]) in the placebo-chemotherapy group (rate difference, 12.2% [95% CI, 3.3%-21.2%]; 1-sided p = 0.004).
- In the neoadjuvant phase, adverse events of grade 3 or higher occurred in 198 patients (89.2%) in the camrelizumab-chemotherapy group and 182 (83.1%) in the placebo-chemotherapy group; serious adverse events occurred in 77 patients (34.7%) in the camrelizumab-chemotherapy group and 50 (22.8%) in the placebo-chemotherapy group, with fatal adverse events occurring in 2 patients (0.9%) in the camrelizumab-chemotherapy group.
Conclusions and relevance
- Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response.